Following the discovery of FN3K (fructosamine 3-kinase), and more recently of FN3KRP (FN3K-related protein), research in our laboratory has been focused on testing the enzymatic deglycation hypothesis and investigating the roles of FN3K and FN3KRP. Thus far, using human erythrocytes as a model system, we have obtained the following evidence of enzymatic deglycation: (a) production of GHb (glycated haemoglobin) by d-glucose in intact erythrocytes is 5-fold lower than in haemolysates; (b) glycation of GHb by d-glucose in intact erythrocytes is 5-fold lower than that by l-glucose; (c) inhibition of ATP production in erythrocytes leads to an acceleration in the rate of GHb production by d-glucose; and (d) inhibition of FN3K in erythrocytes by a competitive inhibitor increases the accumulation of GHb. In spite of these data supporting the enzymatic deglycation hypothesis, some outstanding issues remain. These include, among others, the fact that while the apparent deglycation mechanism does not operate on l-glucose, semi-purified FN3K appears to be able to use both d-and l-fructosamines as substrates. Moreover, analysis of the fructoselysine 3-phosphate content of haemoglobin from diabetic subjects suggests that, in addition to FN3K, another deglycating mechanism may be operative in human erythrocytes. Elucidation of these issues is a challenge in the evolving field of deglycation research. Most important, however, is the question of whether enzymatic deglycation is truly an important defence mechanism or merely an epiphenomenon.
Non-enzymatic glycation/enzymatic deglycation hypothesis
The Maillard reaction in vivo can be mediated by many carbohydrates [1, 2] , including α-dicarbonyls such as 3-deoxyglucosone and methylglyoxal [3] [4] [5] . However, when the overall glycation potential of the various sugars in vivo is assessed, it appears that glucose remains the single most important, if not the dominant, monosaccharide in the nonenzymatic glycation process. For many years it was assumed that this glucose-mediated glycation process was nonenzymatic and relatively simple, at least in its initial stages [6, 7] (Scheme 1).
In 1997 we reported on the observation of an enzymatic activity that can catalyse the breakdown of FL (fructoselysine) on proteins by phosphorylating it to FL3P (FL 3-phosphate), which subsequently decomposes and regenerates unmodified lysine residues [8] . Following the recent purification and cloning of this enzyme FN3K (fructosamine 3-kinase) [9, 10] , we proposed a modification of the nonenzymatic glycation hypothesis of diabetic complications to a non-enzymatic glycation/enzymatic deglycation hypothesis [11] . In this scheme, as depicted in Scheme 2, FN3K acts as a deglycating enzyme by removing the non-enzymatic glycation adducts from proteins at the expense of ATP.
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Evidence of enzymatic deglycation in cells
The evidence in support of the deglycation hypothesis has been garnered from four types of experiments. In designing these experiments, we chose to work with human erythrocytes because they are easy to obtain, are convenient to incubate, are freely permeable to glucose [19, 20] and have relatively high levels of FN3K. Mostly significantly, these cell are unique because they are the only system for which there are a number of well validated and robust methods for measuring intracellular non-enzymatic glycation, such as HbA1c (anionic glycated haemoglobin) and the GHb (total glycated haemoglobin) assay using a phenylboronate affinity resin [21] .
Production of GHb by d-glucose in intact cells and haemolysates
Since an effective deglycation process would require energy, in this first set of experiments we proceeded on the assumption that breakdown of the structural and functional organization of the erythrocytes and the consequent disruption of energy production will interfere with the deglycation process. This, in turn, should result in a greater accumulation of GHb and a higher apparent glycation rate in cell lysates than in intact cells incubated under identical conditions.
In the experiments depicted in Figure 1 , human erythrocytes and haemolysates were incubated in physiological media with D-glucose ranging in concentration from 2.5 to 30 mM. After 7 days of incubation the percentage GHb was assessed by phenylboronate affinity chromatography [21] . As expected, we found that the accumulation of GHb in the haemolysates was consistently higher than in intact cells. These results suggest that intact erythrocytes are capable of controlling or reversing the formation of GHb, and that this
Scheme 2 Non-enzymatic glycation/enzymatic deglycation model
The model depicts the activity of FN3K as an enzyme phosphorylating FL residues on proteins to FL3P, and the postulated activity of FL3P hydrolase in catalysing the decomposition of FL3P to lysine, P i and 3-deoxyglucosone [12] . In this scheme, 3-deoxyglucosone is detoxified either by reduction to 3-deoxyfructose [13] [14] [15] [16] or by oxidation to 3-deoxy-2-ketogluconic acid [17, 18] . AGE, advanced glycation end product.
capacity is lost when the structural/functional integrity of cells is disrupted.
Production of GHb in intact erythrocytes by d-glucose and l-glucose
In order to verify that the results described above were not artifacts of the lysate conditions, we performed additional experiments comparing the glycating activity of D-and L-glucose in intact erythrocytes. Our reasoning was that, while the intrinsic reactivity of L-glucose and D-glucose as non-enzymatic glycating agents is the same, an enzymatic deglycating mechanism is likely to be chirally specific for the natural isomer, D-glucose. We anticipated that the apparent rate of production of GHb by L-glucose in intact cells should be higher than that with D-glucose. As illustrated in Figure 2 , these assumptions were confirmed. The L-glucose-mediated accumulation of GHb was about 5-fold greater than that produced by D-glucose.
The apparent existence of a D-glucose-specific deglycation system was further confirmed by additional incubations utilizing a D-glucose analogue, 6-deoxy-D-glucose, which yielded results virtually identical to the ones obtained with D-glucose. Overall, the rates of accumulation of GHb in intact cells incubated with D-glucose and 6-deoxy-D-glucose were ∼20% of the rate of accumulation of GHb in haemolysates (Table 1 ). In contrast, the apparent rate of glycation of haemoglobin by L-glucose in intact cells was virtually 
Effects of ATP depletion on GHb accumulation in cells incubated with d-glucose
Incubation of erythrocytes with 1-5 mM fluoride results in the inhibition of glycolysis and depletion of ATP without significant cell lysis [22, 23] . If an ATP-dependent deglycation system exits in these cells, then erythrocytes incubated with fluoride should show greater accumulation of GHb than cells incubated with identical concentrations of D-glucose without fluoride. As illustrated in Table 2 , this is indeed the case.
Inhibition of FN3K
As reported by Delpierre et al. [24] , and confirmed in our laboratory, inhibition of FN3K in intact erythrocytes by MF (D-morpholinofructose), in the presence of 200 mM D-glucose, leads to an increased accumulation of GHb, with a parallel increase in haemoglobin-bound FL. Significantly, upon removal of the inhibitor or a decrease in the glucose concentration back to 5 mM, the levels of GHb and haemoglobin-bound FL return within 48 h to near-normal levels. These results suggest that FN3K activity may indeed be involved in controlling the levels of haemoglobin-bound FL and GHb.
Outstanding problems with the hypothesis
While the evidence in favour of the enzymatic deglycation hypothesis is significant, it is far from conclusive. Two unresolved issues, which can be noted in this context, are as follows.
Chiral specificity of deglycation and of FN3K
As illustrated above, the extent of GHb production in intact erythrocytes mediated by L-glucose is significantly higher than that mediated by D-glucose. If FN3K were the sole or most important mechanism in determining this effect, one would expect that this enzyme would be specific for Experiments with cloned FN3K indicate that this is indeed the case. However, in semi-purified FN3K preparations from human erythrocytes, which contain proteins other than FN3K, 3-phosphokinase activities were observed with a variety of D-and L-fructosamines. How these facts fit together into a coherent scheme is not known, but they raise some interesting questions about the function of FN3K in erythrocytes and its relationship with the observed differences in the glycation activity of D-and L-glucose.
Problems with MF as an inhibitor of glycation
The data on the inhibitory effects of MF on FN3K activity in intact erythrocytes are persuasive, but not unambiguous.
While MF appears to inhibit the phosphorylation of FL on haemoglobin, it does so by acting as a substrate of FN3K itself. This leads to very significant accumulation of MF 3-phosphate and 3-deoxyglucosone in cells exposed to MF. Consequently, it is not clear whether the increased levels of GHb measured in the cells exposed to MF are due to inhibition of FN3K activity or to the glycation of haemoglobin by the elevated concentrations of 3-deoxyglucosone. Resolution of this uncertainty will require the development of FN3K inhibitors that do not elevate the intracellular concentrations of 3-deoxyglucosone. The synthesis and characterization such compounds are currently in progress.
Future directions and challenges in testing the hypothesis

Definitive determination of the function of FN3K and its isoenzymes
In mammals, FN3K has a closely related homologue, FN3KRP (FN3K-related protein), which in the human genome is located just 8 kb upstream of FN3K on chromosome 17q25.3. Even though this protein is identical in size to FN3K (309 amino acids) and has 68% sequence identity with it, its function remains unknown. Clonally expressed FN3KRP does not phosphorylate any of the substrates of FN3K, nor does it appear to phosphorylate any of the L-fructosamines examined thus far. Assays for other putative functions, such as FL3P hydrolase activity [12] , were also inconclusive.
Isoforms of both FN3K and FN3KRP are found in almost all eukaryotic organisms whose genomes have been sequenced thus far, including mammals, amphibians, birds, fish, plants and nematodes. Apparent FN3K isoenzymes are also found among many prokaryotic organisms, such as cyanobacteria and staphylococci. Interestingly, FN3K has not been found in yeasts, or insects such as Drosophila. The wide distribution of FN3K and FN3K-like proteins and their high degree of conservation in evolution suggests that these proteins play an important role in cell function. Whether or not this involves deglycation remains an open question.
Determination of the function of FN3K/FN3KRP will probably be best performed by knocking down expression of these genes by RNAi (RNA interference) in an organism such as Caenorhabditis elegans [25, 26] , or knocking out them out in the mouse. If our hypothesis regarding the function of FN3K is correct, its complete suppression or deletion should result in a lethal phenotype or in increased sensitivity to stresses such as hyperglycaemia and hyperthermia.
Identification, purification and cloning of a putative FL3P hydrolase While FL3P decomposes spontaneously to lysine, 3-deoxyglucosone and P i by β-elimination, this process is relatively slow, taking several hours. In the one reported experiment which measured the kinetics of the renal production of 3-deoxyglucosone from labelled FL, the conversion of FL into FL3P and 3-deoxyglucosone occurred within minutes [12] . Consequently, there is good reason to believe that, at least in the kidney, the spontaneous decomposition of FL3P is catalysed by an enzyme that we have tentatively named FL3P hydrolase. Identification and characterization of this protein is an interesting challenge that has not yet been addressed.
Elucidation of the mechanisms of FN3K-independent deglycation
Our measurements of the content of FL3P in individuals with differing levels of HbA1c suggest that the levels of FL3P and FL are very low in individuals with HbA1c levels below 8% (Figure 3) . Interestingly, similar non-linear relationships between HbA1c and the Schiff base of glucose, with a similar threshold of HA1c = 8%, have been reported in two other studies which measured the concentrations of glucosyl-lysine on haemoglobin [27] and glucosylphosphatidylethanolamine in erythrocyte membranes [28] .
These results are surprising, since, if enzymatic deglycation were mediated solely by FN3K, one would anticipate that the concentrations of FL3P and the glucose-derived Schiff bases should be a linear function of glucose concentration, with an intercept at HbA1c = 0%. The fact that this is not so, and the fact that both FL3P and Schiff base concentrations are very low up to HbA1c = 8%, suggest that another deglycating mechanism may be present in human erythrocytes. This FN3K-independent mechanism would have to operate on the glucose-derived Schiff bases, whether formed with lysine or phosphatidylethanolamine. Consequently, we have modified our working model of enzymatic deglycation to account for this apparent mechanism, which could prove to be as important as, or perhaps more important than, FN3K (Scheme 3). 
Conclusion
The discovery of FN3K and enzymatic deglycation has opened new conceptual avenues in research on Maillard reactions in vivo and their relationship to the aetiology of diabetic complications. Given the almost universal distribution of the FN3K gene in Nature, it is very likely that it plays an important role in many cells. The challenge in the coming years is to elucidate what this function(s) is and whether it is related to enzymatic deglycation and diabetic complications.
